Survival Outcomes of Patients With Borderline Resectable and Resectable Pancreatic Adenocarcinoma Treated With Neoadjuvant Short-Course Chemoradiotherapy With Capecitabine-Based vs. Gemcitabine-Based Concurrent Chemotherapy

被引：0
|
作者：
Neibart, S. S. [1 ]
Mamidanna, S. [1 ]
Chundury, A. [1 ]
Sayan, M. [1 ]
Alexander, H. R. [2 ]
August, D. [2 ]
Berim, L. D. [3 ]
Boland, P. M. [3 ]
Grandhi, M. S.
Gulhati, P. [3 ]
Hochster, H. S. [3 ]
Kennedy, T. J. [2 ]
Langan, R. C. [2 ]
Spencer, K. [3 ]
Jabbour, S. K. [1 ]
机构：
[1] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA
[2] Rutgers Canc Inst New Jersey, Dept Surg Oncol, New Brunswick, NJ USA
[3] Rutgers Canc Inst New Jersey, Dept Med Oncol, New Brunswick, NJ USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2081
引用
收藏
页码：E64 / E64
页数：1
相关论文
共 50 条
  • [41] hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
    Wang, Wei
    Yu, Xinzhe
    Li, Hengchao
    Yang, Chuanxin
    Jin, Chen
    Huang, Xinyu
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [42] hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
    Wei Wang
    Xinzhe Yu
    Hengchao Li
    Chuanxin Yang
    Chen Jin
    Xinyu Huang
    BMC Gastroenterology, 23
  • [43] Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01)
    Hayashi, Tsuyoshi
    Nakamura, Toru
    Kimura, Yasutoshi
    Yoshida, Makoto
    Someya, Masanori
    Kawakami, Hiroshi
    Sakuhara, Yusuke
    Katoh, Norio
    Takahashi, Kuniyuki
    Ambo, Yoshiyasu
    Miura, Katsutoshi
    Motoya, Masayo
    Tanaka, Eiichi
    Murakawa, Katsuhiko
    Yamabuki, Takumi
    Yamazaki, Hajime
    Katanuma, Akio
    Hirano, Satoshi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (03): : 606 - 617
  • [44] Long-term outcomes with neoadjuvant chemotherapy with or without stereotactic body radiation therapy in patients with borderline resectable and locally advanced pancreatic adenocarcinoma
    Hill, Colin
    Rosati, Lauren M.
    Hu, Chen
    Fu, Wei
    Sehgal, Shuchi
    Hacker-Prietz, Amy
    He, Jin
    Laheru, Daniel A.
    Zheng, Lei
    Burkhart, Richard A.
    De Jesus-Acosta, Ana
    Le, Dung T.
    Hruban, Ralph H.
    Weiss, Matthew John
    Wolfgang, Christopher Lee
    Narang, Amol
    Herman, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [45] The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer
    Takeda, Tsuyoshi
    Sasaki, Takashi
    Mie, Takafumi
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (04) : 604 - 611
  • [46] Survival outcomes in patients with early-stage, resectable pancreatic cancer: A comparison of gemcitabine and 5-fluorouracil based chemotherapy and chemoradiation regimens
    Kizilbash, Sani Haider
    Ward, Kevin
    Jaiyesimi, Ishmael A.
    Lipscomb, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC)
    Hong, Theodore S.
    Deshpande, Vikram
    Ancukiewicz, Marek
    Yeap, Beow Y.
    Borger, Darrell R.
    Wo, Jennifer Yon-Li
    Boucher, Yves
    Kwak, Eunice Lee
    Clark, Jeffrey W.
    Zhu, Andrew X.
    Blaszkowsky, Lawrence Scott
    Mamon, Harvey J.
    Jain, Rakesh K.
    Ryan, David P.
    DeLaney, Thomas F.
    Fernandez-del Castillo, Carlos
    Duda, Dan G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
    Park, Inkeun
    Choi, Seung Joon
    Kim, Young Saing
    Ahn, Hee Kyung
    Hong, Junshik
    Sym, Sun Jin
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Shin, Yong Ju
    Shin, Dong Bok
    CANCER RESEARCH AND TREATMENT, 2016, 48 (04): : 1264 - 1273
  • [49] Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy
    Karabulut, Senem
    Afsar, Cigdem Usul
    Karabulut, Mehmet
    Alis, Halil
    Erturk, Kayhan
    Karaman, Sule
    Kones, Osman
    Bilgin, Elif
    Tas, Faruk
    JOURNAL OF BUON, 2016, 21 (04): : 895 - 902
  • [50] FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review
    Eshmuminov, Dilmurodjon
    Aminjonov, Botirjon
    Palm, Russell F.
    Malleo, Giuseppe
    Schmocker, Ryan K.
    Abdallah, Raef
    Yoo, Changhoon
    Shaib, Walid L.
    Schneider, Marcel Andre
    Rangelova, Elena
    Choi, Yoo Jin
    Kim, Hongbeom
    Rose, J. Bart
    Patel, Sameer
    Wilson, Gregory C.
    Maloney, Sarah
    Timmermann, Lea
    Sahora, Klaus
    Rossler, Fabian
    Lopez-Lopez, Victor
    Boyer, Emanuel
    Maggino, Laura
    Malinka, Thomas
    Park, Jeong Youp
    Katz, Matthew H. G.
    Prakash, Laura
    Ahmad, Syed A.
    Helton, Scott
    Jang, Jin-Young
    Hoffe, Sarah E.
    Salvia, Roberto
    Taieb, Julien
    He, Jin
    Clavien, Pierre-Alain
    Held, Ulrike
    Lehmann, Kuno
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (07) : 4417 - 4428
12345